Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $9.02M | $14.8M | $16.0M | $79.1M | $6.25M | $0.00 | $7.16M | $28.5M | $72.3M |
| Revenue growth | — | — | 64.1% | 7.8% | 395.6% | -92.1% | -100.0% | — | 298.2% | 153.5% |
| Operating income | -$45.3M | -$52.2M | -$92.7M | -$103M | -$64.8M | -$133M | -$94.1M | -$64.6M | -$45.4M | -$12.1M |
| Operating margin | — | -579.1% | -626.4% | -643.4% | -81.9% | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Net income | -$44.3M | -$42.8M | -$90.8M | -$97.6M | -$62.2M | -$130M | -$93.1M | -$61.2M | -$40.2M | -$6.12M |
| Net margin | — | -474.7% | -613.0% | -611.6% | -78.6% | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| EPS (diluted) | -$2.57 | -$2.41 | -$3.98 | -$3.72 | -$1.75 | -$3.00 | -$23.08 | -$13.38 | -$6.69 | -$0.55 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.9M | $1.86M | -$65.0M | -$84.1M | -$63.0M | -$93.4M | -$84.5M | $22.7M | -$51.1M | -$41.1M |
| Capital expenditures | $147K | $865K | $340K | $1.55M | $470K | $3.10M | $102K | $255K | $28.0K | $66.0K |
| Free cash flow | -$35.0M | $995K | -$65.3M | -$85.6M | -$63.4M | -$96.5M | -$84.6M | $22.5M | -$51.1M | -$41.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28.6M | $82.0M | $41.5M | $46.7M | $59.4M | $45.6M | $52.4M | $19.8M | $38.3M | $58.5M |
| Total assets | $98.1M | $169M | $268M | $340M | $283M | $191M | $102M | $137M | $119M | $258M |
| Total liabilities | $18.2M | $56.2M | $57.4M | $66.7M | $42.7M | $22.1M | $19.1M | $95.7M | $85.8M | $50.8M |
| Shareholders' equity | $79.9M | $113M | $211M | $273M | $241M | $169M | $82.7M | $41.1M | $33.4M | $207M |
| Retained earnings | -$208M | -$251M | -$342M | -$439M | -$502M | -$631M | -$725M | -$786M | -$826M | -$832M |
| Shares (wtd avg diluted) | 17.2M | 20.1M | 25.5M | 32.6M | 34.0M | 43.3M | 4.03M | 4.58M | 6.00M | 11.2M |
Every figure is extracted from ASSEMBLY BIOSCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.